Role of 64CuCl2 PET/CT in Detecting and Staging Muscle-Invasive Bladder Cancer: Comparison with Contrast-Enhanced CT and 18F-FDG PET/CT.

Arnoldo Piccardo, Gianluca Bottoni, Cristina Puppo, Michela Massollo, Martina Ugolini, Mehrdad Shoushtari Zadeh Naseri, Enrico Melani, Laura Tomasello, Monica Boitano, Andrea DeCensi, Beatrice Sambucco, Fabio Campodonico, Vania Altrinetti, Marco Ennas, Alessia Urru, Carlo Luigi Augusto Negro, Luca Timossi, Giorgio Treglia, Carlo Introini, Francesco Fiz
{"title":"Role of <sup>64</sup>CuCl<sub>2</sub> PET/CT in Detecting and Staging Muscle-Invasive Bladder Cancer: Comparison with Contrast-Enhanced CT and <sup>18</sup>F-FDG PET/CT.","authors":"Arnoldo Piccardo, Gianluca Bottoni, Cristina Puppo, Michela Massollo, Martina Ugolini, Mehrdad Shoushtari Zadeh Naseri, Enrico Melani, Laura Tomasello, Monica Boitano, Andrea DeCensi, Beatrice Sambucco, Fabio Campodonico, Vania Altrinetti, Marco Ennas, Alessia Urru, Carlo Luigi Augusto Negro, Luca Timossi, Giorgio Treglia, Carlo Introini, Francesco Fiz","doi":"10.2967/jnumed.124.267474","DOIUrl":null,"url":null,"abstract":"<p><p>Molecular imaging of muscle-invasive bladder cancer (MBC) is restricted to its locoregional and distant metastases, since most radiopharmaceuticals have a urinary excretion that limits the visualization of the primary tumor. <sup>64</sup>CuCl<sub>2</sub> <sub>,</sub> a positron-emitting radiotracer with nearly exclusive biliary elimination, could be well suited to exploring urinary tract neoplasms. In this study, we evaluated the feasibility of <sup>64</sup>CuCl<sub>2</sub>-based staging of patients with MBC; furthermore, we compared the diagnostic capability of this method with those of the current gold standards, that is, contrast-enhanced CT (ceCT) and <sup>18</sup>F-FDG PET/CT. <b>Methods:</b> We prospectively enrolled patients referred to our institution for pathology-confirmed MBC staging/restaging between September 2021 and January 2023. All patients underwent ceCT, <sup>18</sup>F-FDG, and <sup>64</sup>CuCl<sub>2</sub> PET/CT within 2 wk. Patient-based analysis and lesion-based analysis were performed for all of the potentially affected districts (overall, bladder wall, lymph nodes, skeleton, liver, lung, and pelvic soft tissue). <b>Results:</b> Forty-two patients (9 women) were enrolled. Thirty-six (86%) had evidence of disease, with a total of 353 disease sites. On patient-based analysis, ceCT and <sup>64</sup>CuCl<sub>2</sub> PET/CT showed higher sensitivity than <sup>18</sup>F-FDG PET/CT in detecting the primary tumor (<i>P</i> < 0.001); moreover, <sup>64</sup>CuCl<sub>2</sub> PET/CT was slightly more sensitive than <sup>18</sup>F-FDG PET/CT in disclosing soft-tissue lesions (<i>P</i> < 0.05). Both PET methods were more specific and accurate than ceCT in classifying nodal lesions (<i>P</i> < 0.05). On lesion-based analysis, <sup>64</sup>CuCl<sub>2</sub> PET/CT outperformed <sup>18</sup>F-FDG PET/CT and ceCT in detecting disease localizations overall (<i>P</i> < 0.001), in the lymph nodes (<i>P</i> < 0.01), in the skeleton (<i>P</i> < 0.001), and in the soft tissue (<i>P</i> < 0.05). <b>Conclusion:</b> <sup>64</sup>CuCl<sub>2</sub> PET/CT appears to be a sensitive modality for staging/restaging of MBC and might represent a \"one-stop shop\" diagnostic method in these scenarios.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1357-1363"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnumed.124.267474","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Molecular imaging of muscle-invasive bladder cancer (MBC) is restricted to its locoregional and distant metastases, since most radiopharmaceuticals have a urinary excretion that limits the visualization of the primary tumor. 64CuCl2 , a positron-emitting radiotracer with nearly exclusive biliary elimination, could be well suited to exploring urinary tract neoplasms. In this study, we evaluated the feasibility of 64CuCl2-based staging of patients with MBC; furthermore, we compared the diagnostic capability of this method with those of the current gold standards, that is, contrast-enhanced CT (ceCT) and 18F-FDG PET/CT. Methods: We prospectively enrolled patients referred to our institution for pathology-confirmed MBC staging/restaging between September 2021 and January 2023. All patients underwent ceCT, 18F-FDG, and 64CuCl2 PET/CT within 2 wk. Patient-based analysis and lesion-based analysis were performed for all of the potentially affected districts (overall, bladder wall, lymph nodes, skeleton, liver, lung, and pelvic soft tissue). Results: Forty-two patients (9 women) were enrolled. Thirty-six (86%) had evidence of disease, with a total of 353 disease sites. On patient-based analysis, ceCT and 64CuCl2 PET/CT showed higher sensitivity than 18F-FDG PET/CT in detecting the primary tumor (P < 0.001); moreover, 64CuCl2 PET/CT was slightly more sensitive than 18F-FDG PET/CT in disclosing soft-tissue lesions (P < 0.05). Both PET methods were more specific and accurate than ceCT in classifying nodal lesions (P < 0.05). On lesion-based analysis, 64CuCl2 PET/CT outperformed 18F-FDG PET/CT and ceCT in detecting disease localizations overall (P < 0.001), in the lymph nodes (P < 0.01), in the skeleton (P < 0.001), and in the soft tissue (P < 0.05). Conclusion: 64CuCl2 PET/CT appears to be a sensitive modality for staging/restaging of MBC and might represent a "one-stop shop" diagnostic method in these scenarios.

64CuCl2 PET/CT 在肌浸润性膀胱癌的检测和分期中的作用:与对比增强 CT 和 18F-FDG PET/CT 的比较。
肌肉浸润性膀胱癌(MBC)的分子成像仅限于其局部和远处转移,因为大多数放射性药物在尿液中的排泄限制了对原发肿瘤的观察。64CuCl2 是一种正电子发射放射性示踪剂,几乎完全通过胆道排出体外,非常适合用于探查泌尿道肿瘤。在本研究中,我们评估了基于 64CuCl2 对 MBC 患者进行分期的可行性;此外,我们还比较了该方法与当前金标准(即对比增强 CT(ceCT)和 18F-FDG PET/CT)的诊断能力。研究方法我们在 2021 年 9 月至 2023 年 1 月期间前瞻性地招募了转诊到我院进行病理确诊的 MBC 分期/复期患者。所有患者均在2周内接受了ceCT、18F-FDG和64CuCl2 PET/CT检查。对所有可能受影响的区域(整体、膀胱壁、淋巴结、骨骼、肝脏、肺部和盆腔软组织)进行了基于患者的分析和基于病灶的分析。结果显示42 名患者(9 名女性)入组。其中 36 人(86%)有疾病证据,疾病部位共计 353 个。根据对患者的分析,ceCT 和 64CuCl2 PET/CT 在检测原发肿瘤方面的灵敏度高于 18F-FDG PET/CT(P < 0.001);此外,64CuCl2 PET/CT 在揭示软组织病变方面的灵敏度略高于 18F-FDG PET/CT(P < 0.05)。在对结节病变进行分类时,两种 PET 方法的特异性和准确性均高于 ceCT(P < 0.05)。在基于病灶的分析中,64CuCl2 PET/CT 在检测总体病灶定位(P < 0.001)、淋巴结病灶定位(P < 0.01)、骨骼病灶定位(P < 0.001)和软组织病灶定位(P < 0.05)方面均优于 18F-FDG PET/CT 和 ceCT。结论:64CuCl2 PET/CT 似乎是一种用于 MBC 分期/复查的敏感模式,在这些情况下可能是一种 "一站式 "诊断方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信